TURKU, FINLAND / ACCESS Newswire / January 13, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Mr. Jurriaan Dekkers, Chief Financial Officer of the Company, sold 4,000 ordinary shares in Faron at price of £1.822 per share on 12 January 2026.
Further details are set out in the Notification of Dealing Form below.
|
PDMR |
Holding prior to sale |
Number of ordinary shares sold |
Resultant interest in ordinary shares in the Company |
Resultant percentage of voting rights in the Company |
|
Jurriaan Dekkers |
4,000 |
4,000 |
0 |
0.0% |
For more information, please contact:
|
IR Partners, Finland Kare Laukkanen |
+358 50 553 9535 / +44 7 469 766 223 |
|
FINN Partners, US |
+1 847 791-8085 |
|
Cairn Financial Advisers LLP |
+44 (0) 207 213 0880 |
|
Sisu Partners Oy |
+358 (0)40 555 4727 |
About Faron Pharmaceuticals Ltd.
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
|||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a. |
Name |
Jurriaan Dekkers |
|||
|
2 |
Reason for notification |
||||
|
a. |
Position/Status |
Chief Financial Officer |
|||
|
b. |
Initial notification/ |
Initial Notification |
|||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a. |
Name |
Faron Pharmaceuticals Ltd. |
|||
|
b. |
LEI |
7437009H31TO1DC0EB42 |
|||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a. |
Description of the financial instrument, type of instrument Identification Code |
Ordinary Shares ISIN: FI4000153309 |
|||
|
b. |
Nature of the transaction |
Sale of Ordinary Shares |
|||
|
Price(s) per share (p) |
Volume(s) |
||||
|
£1.822 |
4,000 |
||||
|
d. |
Aggregated information |
4,000 |
|||
|
e. |
Date of the transaction |
12/01/2026 |
|||
|
f. |
Place of the transaction |
London Stock Exchange, AIM |
|||
SOURCE: Faron Pharmaceuticals
View the original press release on ACCESS Newswire
